ARS Pharmaceuticals, Inc. Common Stock

SPRYNASDAQUSD
4.76 USD
0.00 (0.00%)AT CLOSE (11:59 AM EDT)
4.95
0.19 (3.99%)
POST MARKET (AS OF 07:43 PM EDT)
Post Market
AS OF 07:43 PM EDT
4.95
0.19 (3.99%)
🔴Market: CLOSED

ARS Pharmaceuticals, Inc. Common Stock (SPRY) is currently trading at $4.76. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. SPRY is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Sep 11, 2026.

Open?$5.13
High?$5.19
Low?$4.73
Prev. Close?$4.76
Volume?2.6M
Avg. Volume?1.7M
VWAP?$4.91
Rel. Volume?1.50x
Bid / Ask
Bid?$4.80 × 200
Ask?$5.17 × 1.0K
Spread?$0.37
Midpoint?$4.98
Valuation & Ratios
Market Cap?473.4M
Shares Out?99.4M
Float?49.0M
Float %?49.3%
P/E Ratio?N/A
P/B Ratio?37.83
EPS?-$2.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Employees
200
Market Cap
473.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2022-11-09
Address
11682 EL CAMINO REAL, SUITE 300
SAN DIEGO, CA 92130
Phone: 858-771-9307
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
35
Short Sent.?
10
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.81Distress
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?47.38%Squeeze Risk
Short Interest?23.2M
Days to Cover?14.1
Free Float49.0M
Avg Daily Volume1.6M
Settlement Date2026-08-31
Financial Health
Current Ratio?3.48Strong
Quick Ratio?3.28Strong
Cash Ratio?0.13Low
Debt/Equity?13.72High
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
3
37.83HIGH
P/S?
Peers
100
S&P
38
4.05FAIR
P/FCF?
N/A
EV/EBITDA?
S&P
97
-3.0CHEAP
EV/Sales?
Peers
100
S&P
32
5.45FAIR
Returns & Efficiency
ROE?
S&P
3
-1,719.7%WEAK
ROA?
S&P
3
-86.2%WEAK
Cash Flow & Enterprise
FCF?$-196602000
Enterprise Value?$636.8M
Fundamentals ratios updated end of day